↓ Skip to main content

Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells

Overview of attention for article published in Clinical and Translational Allergy, September 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

f1000
1 research highlight platform

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
Published in
Clinical and Translational Allergy, September 2013
DOI 10.1186/2045-7022-3-29
Pubmed ID
Authors

Marcia A Chan, Nicole M Gigliotti, Abby L Dotson, Lanny J Rosenwasser

Abstract

Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and animal models support the hypothesis that omalizumab inhibits IgE synthesis by B cells and causes elimination of IgE-expressing cells either by induction of apoptosis or induction of anergy or tolerance.

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 2%
Unknown 54 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 20%
Student > Bachelor 9 16%
Student > Ph. D. Student 9 16%
Student > Doctoral Student 5 9%
Other 4 7%
Other 9 16%
Unknown 8 15%
Readers by discipline Count As %
Medicine and Dentistry 18 33%
Agricultural and Biological Sciences 14 25%
Biochemistry, Genetics and Molecular Biology 5 9%
Immunology and Microbiology 5 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Other 1 2%
Unknown 8 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2014.
All research outputs
#7,807,590
of 12,443,702 outputs
Outputs from Clinical and Translational Allergy
#292
of 366 outputs
Outputs of similar age
#99,233
of 192,645 outputs
Outputs of similar age from Clinical and Translational Allergy
#5
of 22 outputs
Altmetric has tracked 12,443,702 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 366 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,645 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.